(19)
(11) EP 3 268 367 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.11.2022 Bulletin 2022/46

(45) Mention of the grant of the patent:
05.10.2022 Bulletin 2022/40

(21) Application number: 16762275.2

(22) Date of filing: 07.03.2016
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61K 45/06(2006.01)
 C07D 495/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 45/06; C07D 495/04; C07D 487/04; A61K 31/4985; A61K 31/519; A61K 31/53; A61K 31/5377; A61K 31/635
(86) International application number:
PCT/US2016/021116
(87) International publication number:
WO 2016/144844 (15.09.2016 Gazette 2016/37)

(54)

CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY

CARBOXAMIDINHIBITOREN DER IRAK4-AKTIVITÄT

CARBOXAMIDES UTILISÉS COMME INHIBITEURS DE L'ACTIVITÉ DE L'IRAK4

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.03.2015 US 201562132183 P

(43) Date of publication of application:
17.01.2018 Bulletin 2018/03

(73) Proprietor: Merck Sharp & Dohme LLC
Rahway, New Jersey 07065-0907 (US)

(72) Inventors:
  • LIM, Jongwon
    Boston, Massachusetts 02115-5727 (US)
  • ALTMAN, Michael, D.
    Boston, Massachusetts 02115-5727 (US)
  • CHILDERS, Matthew, L.
    Boston, Massachusetts 02115-5727 (US)
  • GIBEAU, Craig, R.
    Boston, Massachusetts 02115-5727 (US)
  • HO, Ginny Dai
    Murray Hill, New Jersey 07074 (US)
  • TSUI, Honchung
    Shanghai 201203 (CN)

(74) Representative: Merck Sharp & Dohme LLC 
120 Moorgate
London EC2M 6UR
London EC2M 6UR (GB)


(56) References cited: : 
WO-A1-2005/012256
WO-A2-2013/163159
US-A1- 2010 323 994
US-A1- 2014 194 404
US-A1- 2015 005 499
 WO-A1-2010/051549
US-A1- 2004 209 886
US-A1- 2012 028 919
US-A1- 2014 303 149
US-B1- 6 414 013
   
  • JEFFREY J. MASON ET AL: "Synthetic Studies of Cephalandole Alkaloids and the Revised Structure of Cephalandole A", JOURNAL OF NATURAL PRODUCTS., vol. 71, no. 8, 1 August 2008 (2008-08-01) , pages 1447-1450, XP055487755, US ISSN: 0163-3864, DOI: 10.1021/np800334j
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).